|Bid||0.00 x 1200|
|Ask||0.00 x 3200|
|Day's range||7.59 - 7.96|
|52-week range||5.42 - 33.64|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||11.97|
|Earnings date||10 Aug 2022 - 15 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||30.00|
AbCellera Biologics Inc. ( NASDAQ:ABCL ) shareholders will have a reason to smile today, with the analysts making...
Shares of contract drug developer AbCellera Biologics (NASDAQ: ABCL) are down 10% as of 12:04 p.m. ET today, according to data from S&P Global Market Intelligence, following Piper Sandler's lowered price target despite a seemingly strong earnings report. For the three-month stretch ending March 31, biopharma outfit AbCellera Biologics turned $316.6 million worth of revenue into earnings of $0.54 per share. While AbCellera Biologics' CEO Carl Hansen is unsurprisingly optimistic about the future, that's a future in which the drugs' combined revenue contribution could fade -- significantly.
AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of 14.89% and 22.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?